Investigational Drug Information for Bevasiranib
✉ Email this page to a colleague
What is the drug development status for Bevasiranib?
Bevasiranib is an investigational drug.
There have been 5 clinical trials for Bevasiranib.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2009.
The most common disease conditions in clinical trials are Macular Degeneration, Macular Edema, and Edema. The leading clinical trial sponsors are OPKO Health, Inc. and [disabled in preview].
Summary for Bevasiranib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 145 |
| WIPO Patent Applications | 107 |
| Japanese Patent Applications | 20 |
| Clinical Trial Progress | Phase 2 (2009-11-01) |
| Vendors | 0 |
Recent Clinical Trials for Bevasiranib
| Title | Sponsor | Phase |
|---|---|---|
| Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON) | OPKO Health, Inc. | Phase 3 |
| Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD | OPKO Health, Inc. | Phase 3 |
| Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema | OPKO Health, Inc. | Phase 2 |
Clinical Trial Summary for Bevasiranib
Top disease conditions for Bevasiranib
Top clinical trial sponsors for Bevasiranib
US Patents for Bevasiranib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
